BI Asset Management Fondsmaeglerselskab A S Trims Position in Halozyme Therapeutics, Inc. $HALO

Key Points

• BI Asset Management cut its Halozyme Therapeutics stake by 14.8% in the fourth quarter, though it still held 246,143 shares worth about $16.6 million. Institutional investors remain heavily involved, owning 97.79% of the company.
• Analyst sentiment is constructive: Zacks and several other firms raised earnings estimates or maintained bullish ratings, while the consensus rating remains Moderate Buy with an average target price of $81.60.
• Halozyme reported strong quarterly results, with EPS of $1.60 beating estimates and revenue rising 42.2% year over year to $376.71 million. The company also issued FY2026 guidance of $7.75 to $8.25 EPS.

BI Asset Management Fondsmaeglerselskab A S lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 246,143 shares of the biopharmaceutical company's stock after selling 42,809 shares during the period. BI Asset Management Fondsmaeglerselskab A S owned 0.21% of Halozyme Therapeutics worth $16,565,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Empowered Funds LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at about $755,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter valued at about $195,000. Hsbc Holdings PLC grew its position in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company's stock worth $522,000 after buying an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 174 shares in the last quarter. Finally, Baird Financial Group Inc. raised its stake in shares of Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company's stock worth $577,000 after acquiring an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Key Headlines Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Insider Activity

In other news, Director Bernadette Connaughton sold 1,625 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $66.21, for a total value of $107,591.25. Following the sale, the director directly owned 43,669 shares of the company's stock, valued at $2,891,324.49. This represents a 3.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the business's stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total transaction of $599,087.48. Following the completion of the transaction, the chief operating officer owned 7,055 shares of the company's stock, valued at approximately $477,200.20. This represents a 55.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 122,107 shares of company stock valued at $8,254,834 in the last ninety days. Insiders own 2.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. UBS Group reiterated a "buy" rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. Morgan Stanley reduced their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an "overweight" rating for the company in a research note on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, May 16th. Benchmark reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Wednesday. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, May 12th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $81.60.

Halozyme Therapeutics Stock Down 0.1%

NASDAQ:HALO opened at $71.53 on Friday. The company has a market cap of $8.48 billion, a PE ratio of 25.73, a P/E/G ratio of 0.30 and a beta of 0.88. Halozyme Therapeutics, Inc. has a twelve month low of $51.06 and a twelve month high of $82.22. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The company's 50 day moving average is $66.79 and its two-hundred day moving average is $68.74.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The business had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The business's revenue for the quarter was up 42.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.